Clinical and Genetic Characterization of 51 Patients with Congenital Fibrinogen Disorders from China

Abstract

Objective To investigate the classification, clinical manifestations, laboratory findings, and genetic mutations associated with hereditary fibrinogen disorders in Chinese population.

Methods Between February 2015 and February 2022, 65 patients with congenital fibrinogen disorders (CFD) were identified at Wuhan Union Hospital. Comprehensive data were available for 51 patients, allowing for a retrospective analysis.

Results The cohort comprised 17 males (33.3%) and 34 females (66.7%), with a median diagnosis age of 35.0 years (interquartile range: 25.5–42.5). Of the patients, 35 (68.6%) were diagnosed with dysfibrinogenemia, 8 (15.7%) with hypofibrinogenemia, 7 (13.7%) with hypodysfibrinogenemia, and 1 (2.0%) with afibrinogenemia. The median diagnosis ages for the asymptomatic, Grade 1, Grade 2, and Grade 3 groups were 44.5 years (range: 37–58.5), 28 years (22.5–36.5), 35.5 years (21.75–41), and 28 years (22.75–30.75), respectively. The asymptomatic group had the latest diagnosis age, whereas Grade 3 had the earliest. A negative correlation was observed between Fg:C levels and bleeding severity (rs = − 0.2937, p = 0.0365). In total, 52 variants were found in 51 unrelated patients, with one patient carrying two mutations. The 37 distinct mutations included 11 in FGA, 3 in FGB, and 23 in FGG.

Conclusion This study investigates the clinical, laboratory, and genetic characteristics of patients with CFD in China, revealing a negative correlation between Fg:C levels and bleeding severity. Female patients are at higher risk for gynecological complications due to physiological traits. Additionally, R35 in FGA and R301 in FGG were identified as hotspot mutations.

Keywords

bleeding - inherited coagulation disorders - thrombosis - gene mutations

Ethical Approval Statement

The study was approved by the Ethics Committee of the Union Hospital affiliated to Huazhong University of Science and Technology, Wuhan, China.

Authors' Contribution

Y.C. and H.L.: Drafted the manuscript, analyzed the data, participated in data curation, and contributed to writing. L.V.T. and Y.H.: Designed the study, obtained funding for the project, and contributed to conceptualization, methodology, project administration, and supervision. Y.X. and Z.C.: Responsible for data acquisition and contributed to investigation and resources. W.L.: Contributed to data analysis and interpretation. T.W.: Provided technical support and contributed to software and visualization. All authors reviewed the manuscript.

^* These authors are co-first authors.

Publikationsverlauf

Eingereicht: 15. Oktober 2024

Angenommen: 16. Dezember 2024

Accepted Manuscript online:
13. Januar 2025

Artikel online veröffentlicht:
31. Januar 2025

• References

• 1 Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3 (08) 1894-1904
• 2 Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936: 11-30
• 3 Kattula S, Byrnes JR, Wolberg AS. Fibrinogen and fibrin in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2017; 37 (03) e13-e21
• 4 Vu D, Bolton-Maggs PH, Parr JR, Morris MA, de Moerloose P, Neerman-Arbez M. Congenital afibrinogenemia: identification and expression of a missense mutation in FGB impairing fibrinogen secretion. Blood 2003; 102 (13) 4413-4415
• 5 Simurda T, Brunclikova M, Asselta R. et al. Genetic variants in the FGB and FGG genes mapping in the beta and gamma nodules of the fibrinogen molecule in congenital quantitative fibrinogen disorders associated with a thrombotic phenotype. Int J Mol Sci 2020; 21 (13) 4616
• 6 Klykov O, van der Zwaan C, Heck AJR, Meijer AB, Scheltema RA. Missing regions within the molecular architecture of human fibrin clots structurally resolved by XL-MS and integrative structural modeling. Proc Natl Acad Sci U S A 2020; 117 (04) 1976-1987
• 7 Lim BC, Ariëns RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361 (9367) 1424-1431
• 8 Matsuda M, Sugo T. Hereditary disorders of fibrinogen. Ann N Y Acad Sci 2001; 936: 65-88
• 9 Casini A, Blondon M, Lebreton A. et al. Natural history of patients with congenital dysfibrinogenemia. Blood 2015; 125 (03) 553-561
• 10 Valiton V, Hugon-Rodin J, Fontana P, Neerman-Arbez M, Casini A. Obstetrical and postpartum complications in women with hereditary fibrinogen disorders: a systematic literature review. Haemophilia 2019; 25 (05) 747-754
• 11 Casini A, Abdul Kadir R, Abdelwahab M. et al. Management of pregnancy and delivery in congenital fibrinogen disorders: communication from the ISTH SSC Subcommittee on Factor XIII and Fibrinogen. J Thromb Haemost 2024; 22 (05) 1516-1521
• 12 Peyvandi F, Palla R, Menegatti M. et al; European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10 (04) 615-621
• 13 Tang L, Wang H-F, Lu X. et al. Common genetic risk factors for venous thrombosis in the Chinese population. Am J Hum Genet 2013; 92 (02) 177-187
• 14 Ramanan R, McFadyen JD, Perkins AC, Tran HA. Congenital fibrinogen disorders: Strengthening genotype-phenotype correlations through novel genetic diagnostic tools. Br J Haematol 2023; 203 (03) 355-368
• 15 Weinstock N, Ntefidou M. ISTH/SSC Fibrinogen Subcommittee, GTH Fibrinogen Working Party. SSC International Collaborative Study to establish the first high fibrinogen plasma reference material for use with different fibrinogen assay techniques. J Thromb Haemost 2006; 4 (08) 1825-1827
• 16 Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood 2015; 125 (13) 2052-2061
• 17 Shen MC, Wang JD, Tsai W. et al. Clinical features and genetic defect in six index patients with congenital fibrinogen disorders: three novel mutations with one common mutation in Taiwan's population. Haemophilia 2021; 27 (06) 1022-1027
• 18 Miesbach W, Schenk J, Alesci S, Lindhoff-Last E. Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia. Thromb Res 2010; 126 (06) e428-e433
• 19 Shapiro SE, Phillips E, Manning RA. et al. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol 2013; 160 (02) 220-227
• 20 Casini A, Undas A, Palla R, Thachil J, de Moerloose P. Subcommittee on Factor XIII and Fibrinogen. Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16 (09) 1887-1890
• 21 Xiang L, Luo M, Yan J. et al. Combined use of Clauss and prothrombin time-derived methods for determining fibrinogen concentrations: screening for congenital dysfibrinogenemia. J Clin Lab Anal 2018; 32 (04) e22322
• 22 Mohsenian S, Palla R, Menegatti M. et al. Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the prospective rare bleeding disorders database. Blood Adv 2024; 8 (06) 1392-1404
• 23 Walter S, Stabler S, Lefkowitz JB. Fibrinogen Denver: a dysfibrinogenemia associated with an abnormal Reptilase time and significant bleeding. Haemophilia 2006; 12 (04) 393-397
• 24 de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013; 39 (06) 585-595
• 25 Vu D, Di Sanza C, Caille D. et al. Quality control of fibrinogen secretion in the molecular pathogenesis of congenital afibrinogenemia. Hum Mol Genet 2005; 14 (21) 3271-3280
• 26 Casini A, Blondon M, Tintillier V. et al. Mutational epidemiology of congenital fibrinogen disorders. Thromb Haemost 2018; 118 (11) 1867-1874
• 27 Wan Y, Li T, Zhang W. et al. Mutations in inherited fibrinogen disorders correlated with clinical features in the Chinese population. J Thromb Thrombolysis 2021; 51 (04) 1127-1131
• 28 Castaman G, Giacomelli SH, Biasoli C, Contino L, Radossi P. Risk of bleeding and thrombosis in inherited qualitative fibrinogen disorders. Eur J Haematol 2019; 103 (04) 379-384
• 29 Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood 2005; 106 (13) 4176-4183
• 30 Palla R, Siboni SM, Menegatti M, Musallam KM, Peyvandi F. European Network of Rare Bleeding Disorders (EN-RBD) group. Establishment of a bleeding score as a diagnostic tool for patients with rare bleeding disorders. Thromb Res 2016; 148: 128-134
• 31 Hayes T. Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med 2002; 126 (11) 1387-1390
• 32 Liu CY, Koehn JA, Morgan FJ. Characterization of fibrinogen New York 1. A dysfunctional fibrinogen with a deletion of B beta(9-72) corresponding exactly to exon 2 of the gene. J Biol Chem 1985; 260 (07) 4390-4396
• 33 Koopman J, Haverkate F, Grimbergen J. et al. Molecular basis for fibrinogen Dusart (A alpha 554 Arg–>Cys) and its association with abnormal fibrin polymerization and thrombophilia. J Clin Invest 1993; 91 (04) 1637-1643
• 34 Wada Y, Lord ST. A correlation between thrombotic disease and a specific fibrinogen abnormality (A alpha 554 Arg–>Cys) in two unrelated kindred, Dusart and Chapel Hill III. Blood 1994; 84 (11) 3709-3714
• 35 Koopman J, Haverkate F, Lord ST, Grimbergen J, Mannucci PM. Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of B beta 68 Ala—-Thr. J Clin Invest 1992; 90 (01) 238-244
• 36 Koopman J, Haverkate F, Grimbergen J. et al. Abnormal fibrinogens IJmuiden (B beta Arg14—-Cys) and Nijmegen (B beta Arg44—-Cys) form disulfide-linked fibrinogen-albumin complexes. Proc Natl Acad Sci U S A 1992; 89 (08) 3478-3482
• 37 Franchini M, Favaloro EJ, Targher G, Lippi G. ABO blood group, hypercoagulability, and cardiovascular and cancer risk. Crit Rev Clin Lab Sci 2012; 49 (04) 137-149
• 38 Mehic D, Hofer S, Jungbauer C. et al. Association of ABO blood group with bleeding severity in patients with bleeding of unknown cause. Blood Adv 2020; 4 (20) 5157-5164
• 39 Watanabe K, Shibuya A, Ishii E. et al. Identification of simultaneous mutation of fibrinogen alpha chain and protein C genes in a Japanese kindred. Br J Haematol 2003; 120 (01) 101-108
• 40 Neerman-Arbez M, Honsberger A, Antonarakis SE, Morris MA. Deletion of the fibrinogen [correction of fibrogen] alpha-chain gene (FGA) causes congenital afibrogenemia. J Clin Invest 1999; 103 (02) 215-218
• 41 Spena S, Duga S, Asselta R. et al. Congenital afibrinogenaemia caused by uniparental isodisomy of chromosome 4 containing a novel 15-kb deletion involving fibrinogen A alpha-chain gene. Eur J Hum Genet 2004; 12 (11) 891-898
• 42 Li X, Zhou T, Feng X, Yau ST, Yau SS. Exploring geometry of genome space via Grassmann manifolds. Innovation (Camb) 2024; 5 (05) 100677
• 43 Dong C, Wei P, Jian X. et al. Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. Hum Mol Genet 2015; 24 (08) 2125-2137